94 related articles for article (PubMed ID: 6726304)
1. Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma.
King ME; Pfeifle CE; Howell SB
J Clin Oncol; 1984 Jun; 2(6):662-9. PubMed ID: 6726304
[TBL] [Abstract][Full Text] [Related]
2. Extremely prolonged continuous intraperitoneal infusion of cytosine arabinoside.
Kirmani S; Zimm S; Cleary SM; Mowry J; Howell SB
Cancer Chemother Pharmacol; 1990; 25(6):454-8. PubMed ID: 2311175
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal cytosine arabinoside administered in sequence with systemic cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Campora E; Bruzzone M; Chiara S; Alama A; Iskra L; Carnino F; Parodi S; Foglia G; Ragni N; Rosso R
Gynecol Oncol; 1990 Apr; 37(1):39-43. PubMed ID: 2323610
[TBL] [Abstract][Full Text] [Related]
4. Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia.
Yang JL; Cheng EH; Capizzi RL; Cheng YC; Kute T
J Clin Invest; 1985 Jan; 75(1):141-6. PubMed ID: 4038404
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine after intraperitoneal administration].
Noda T; Oku M; Kiyozuka Y; Maruyama M; Adachi S; Akada S; Okamura Y; Ichijo M
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2929-35. PubMed ID: 3178241
[TBL] [Abstract][Full Text] [Related]
6. Cytosine arabinoside cerebrospinal fluid kinetics.
Zimm S; Collins JM; Miser J; Chatterji D; Poplack DG
Clin Pharmacol Ther; 1984 Jun; 35(6):826-30. PubMed ID: 6587957
[TBL] [Abstract][Full Text] [Related]
7. High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides.
Sinkule JA; Evans WE
J Chromatogr; 1983 May; 274():87-93. PubMed ID: 6575975
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Dedrick RL; Myers CE; Bungay PM; DeVita VT
Cancer Treat Rep; 1978 Jan; 62(1):1-11. PubMed ID: 626987
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity.
Markman M; Cleary S; Lucas WE; Howell SB
J Clin Oncol; 1985 Jul; 3(7):925-31. PubMed ID: 3894586
[TBL] [Abstract][Full Text] [Related]
10. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity.
Markman M; Howell SB; Lucas WE; Pfeifle CE; Green MR
J Clin Oncol; 1984 Dec; 2(12):1321-6. PubMed ID: 6542584
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.
Markman M; Hakes T; Reichman B; Hoskins W; Rubin S; Jones W; Almadrones L; Yordan EL; Eriksson J; Lewis JL
J Clin Oncol; 1991 Feb; 9(2):204-10. PubMed ID: 1988569
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
Hashida M; Kojima T; Muranishi S; Sezaki H
Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.
Esteva FJ; Soh LT; Holmes FA; Plunkett W; Meyers CA; Forman AD; Hortobagyi GN
Cancer Chemother Pharmacol; 2000; 46(5):382-6. PubMed ID: 11127942
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of cis-platinum and cytosine arabinoside on ovarian carcinoma cell lines, demonstrated by dual-parameter flow cytometry.
Kingston RE; Sevin BU; Ramos R; Saks M; Donato D; Jarrell MA; Averette HE
Gynecol Oncol; 1989 Mar; 32(3):282-7. PubMed ID: 2920948
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of combined intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model.
Berek JS; Schink JC; Knox RM
Obstet Gynecol; 1989 Oct; 74(4):663-6. PubMed ID: 2797645
[TBL] [Abstract][Full Text] [Related]
17. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma.
D'Acquisto R; Markman M; Hakes T; Rubin S; Hoskins W; Lewis JL
J Clin Oncol; 1988 Apr; 6(4):689-95. PubMed ID: 3128649
[TBL] [Abstract][Full Text] [Related]
19. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer.
Markman M; Hakes T; Reichman B; Lewis JL; Rubin S; Jones W; Almadrones L; Hoskins W
J Clin Oncol; 1991 Jun; 9(6):978-82. PubMed ID: 2033432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
